Sunitinib and everolimus in pancreatic neuroendocrine tumors

Tumori. 2012 May-Jun;98(3):394. doi: 10.1177/030089161209800319.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anemia / chemically induced
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Disease-Free Survival
  • Double-Blind Method
  • Everolimus
  • Humans
  • Hypertension / chemically induced
  • Indoles / administration & dosage*
  • Indoles / adverse effects
  • Neuroendocrine Tumors / drug therapy*
  • Neutropenia / chemically induced
  • Pancreatic Neoplasms / drug therapy*
  • Pyrroles / administration & dosage*
  • Pyrroles / adverse effects
  • Randomized Controlled Trials as Topic
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • Stomatitis / chemically induced
  • Sunitinib
  • Treatment Outcome

Substances

  • Indoles
  • Pyrroles
  • Everolimus
  • Sunitinib
  • Sirolimus